Item 2.01 Completion of Acquisition or Disposition of Assets

On December 30, 2022, Shineco Life Science Research Co., Ltd. ("Subsidiary"), a company established under the laws of China and indirect wholly owned subsidiary of Shineco, Inc. (the "Company") closed the acquisition of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd., a company established under the laws of China ("Biowin") pursuant to the previously announced stock purchase agreement, dated as of October 21, 2022, among Beijing Kanghuayuan Medicine Information Consulting Co., Ltd., a company established under the laws of China ("Seller") Biowin, the Company and Subsidiary (the "Agreement").

As the consideration for the acquisition, the Company paid to Seller US $9 million in cash and the Company issued 3,260,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock") to the equity holders of Biowen or any persons designated by Biowen.

According to the Supplementary Agreement, dated as of December 30, 2022, by and among the Subsidiary, the Seller and Biowin, the Seller enjoys 51% of the issued equity interests of Biowin before January 1, 2023, and will transfer the 51% of the issued equity interests of Biowin together with its controlling rights of production and operation of Biowin to the Subsidiary from January 1, 2023.

The foregoing summary of the Agreement is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities.

The description of the Shares issued to the equity holders of Seller in Item 2.01 of this Report is incorporated by reference into this Item 3.02. The Company issued an aggregate of 3,260,000 Shares pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering pursuant to Regulation S under the Securities Act to non-United States residents who are not a "U.S. person" as defined in Rule 902(k) of Regulation S and are not acquiring the Shares for the account or benefit of any U.S. person.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

The financial statements required by this item will be filed by amendment to this Current Report on Form 8-K within 71 calendar days after the date on which this Current Report is required to be filed.

(b) Pro Forma Financial Information.

The pro forma financial information required by this item will be filed by amendment to this Current Report on Form 8-K within 71 calendar days after the date on which this Current Report is required to be filed.





(d) Exhibits:



Exhibit No.   Description

10.1*           Stock Purchase Agreement, dated as of October 21, 2022, by and
              among Shineco, Inc., Shineco Life Science Research Co., Ltd.,
              Beijing Kanghuayuan Medicine Information Consulting Co., Ltd. and
              Changzhou Biowin Pharmaceutical Co., Ltd.
10.2            Supplementary Agreement to the Stock Purchase Agreement, dated as
              of December 30, 2022, by and among Beijing Kanghuayuan Medicine
              Information Consulting Co., Ltd., Shineco Life Science Research Co.,
              Ltd. and Changzhou Biowin Pharmaceutical Co., Ltd.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document and included as Exhibit 101).

*Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such omitted schedules to the Securities and Exchange Commission upon request.

© Edgar Online, source Glimpses